Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Chinese guidelines on the diagnosis and treatment of primary lung cancer 
(2011 version)].
Zhi X, Wu Y, Ma S, Wang T, Wang C, Wang J, Shi Y, Lu Y, Liu L, Liu D, Chen D, Yang Y, Du X, Bu H, Zhou Q, Jang G, Han B, Cheng G, Cheng Y, Jiao S. Zhi X, et al. Among authors: han b. Zhongguo Fei Ai Za Zhi. 2012 Dec;15(12):677-88. doi: 10.3779/j.issn.1009-3419.2012.12.01. Zhongguo Fei Ai Za Zhi. 2012. PMID: 23249713 Free PMC article. Chinese. No abstract available.
[Taxol-resistant Non-small cell lung cancer and microtubulin.].
Chu T, Han B. Chu T, et al. Among authors: han b. Zhongguo Fei Ai Za Zhi. 2008 Apr 20;11(2):273-5. doi: 10.3779/j.issn.1009-3419.2008.02.018. Zhongguo Fei Ai Za Zhi. 2008. PMID: 20731917 Free article. Chinese. No abstract available.
Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011).
Zhi XY, Wu YL, Bu H, Cheng G, Cheng Y, Du X, Han BH, Jiang GN, Jiao SC, Liu DR, Liu LX, Lu Y, Ma SL, Shi YK, Wang CL, Wang J, Wang TY, Yang Y, Zhou QH; Lung Cancer Diagnosis and Treatment Expert Panel of the Chinese Ministry of Health. Zhi XY, et al. J Thorac Dis. 2012 Feb;4(1):88-101. doi: 10.3978/j.issn.2072-1439.2010.08.01. J Thorac Dis. 2012. PMID: 22295172 Free PMC article. No abstract available.
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.
Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Zhang L, et al. Among authors: han b. Lancet Oncol. 2012 May;13(5):466-75. doi: 10.1016/S1470-2045(12)70117-1. Epub 2012 Apr 17. Lancet Oncol. 2012. PMID: 22512843 Clinical Trial.
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M. Wu YL, et al. Among authors: han b. Asia Pac J Clin Oncol. 2012 Sep;8(3):232-43. doi: 10.1111/j.1743-7563.2012.01518.x. Epub 2012 Apr 23. Asia Pac J Clin Oncol. 2012. PMID: 22897752 Clinical Trial.
VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.
Zhi X, Gao W, Han B, Yang Y, Li H, Liu D, Wang C, Min G, Long H, Rigas JR, Carey M, Jahan T, Sammann A, Reza J, Wang D, Mann MJ, Jablons DM, He J; China Clinical Trials Consortium. Zhi X, et al. Among authors: han b. J Thorac Dis. 2013 Oct;5(5):578-84. doi: 10.3978/j.issn.2072-1439.2012.02.05. J Thorac Dis. 2013. PMID: 24255769 Free PMC article.
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.
Hu Z, Cheng Y, Zhang H, Zhou C, Han B, Zhang Y, Huang C, Chang J, Song X, Liang J, Liang H, Bai C, Yu S, Chen J, Wang J, Pan H, Chitkara DK, Hille DA, Zhang L. Hu Z, et al. Among authors: han b. Support Care Cancer. 2014 Apr;22(4):979-87. doi: 10.1007/s00520-013-2043-9. Epub 2013 Nov 26. Support Care Cancer. 2014. PMID: 24276953 Clinical Trial.
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
Zhao H, Fan Y, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Wang M, Zhang L; INFORM investigators. Zhao H, et al. Among authors: han b. J Thorac Oncol. 2015 Apr;10(4):655-64. doi: 10.1097/JTO.0000000000000445. J Thorac Oncol. 2015. PMID: 25546556 Free article. Clinical Trial.
9,371 results